Skip to main content
OpenTrials
Completed

NCT Number: NCT00898599

Prebiotics and Immune Function in Middle Aged Humans

Prebiotics are naturally occurring carbohydrates found in a variety of edible plants. They are not digested by mammalian enzymes, and so reach the gut intact, where they are fermented by some species of intestinal bacteria. This fermentation is thought to have several benefits for the host including improving immune function. There are numerous methods available for assessing the human immune response. Response to vaccination is thought to be a good method for this. Not many studies have examined the effect of prebiotics on the human immune response to vaccination. Thus the investigators propose to test the effect of a prebiotic on the immune response in healthy volunteers including their response to the current flu vaccine. The investigators hypothesise that the prebiotic will enhance the immune response including the response to the vaccine.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

45 year–66 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

University of Southampton

Southampton, SO16 6YD, United Kingdom

About this study

Prebiotics are naturally occurring carbohydrates found in a variety of edible plants. They are not digested by mammalian enzymes, and so reach the gut intact, where they are fermented by some species of intestinal bacteria. This fermentation is thought to have several benefits for the host including improving the immune response. Inulin-type fructans (oligofructose and inulin) are classified as prebiotics. Inulin is found naturally in significant amounts in a variety of plants foods, such as bananas, leeks, onions, artichokes, wheat and chicory. Synergy1 is a prebiotic preparation produced by Beneo-Orafti, and containing a mixture of oligofructose and inulin derived from chicory. Fructooligosaccharides including Synergy1 are widely used by the food industry and are commonly found as a source of insoluble fibre in many biscuit, bakery, cereal and dairy products.

There is increasing evidence that the changes in the intestinal microflora that occur with the consumption of fructooligosaccharides can modulate immune parameters, not only in the gut-associated lymphoid tissue, but also secondary lymphoid tissues and the peripheral circulation. Much of the evidence for beneficial effects of fructooligosaccharides on immune function comes from animal models e.g. rats, mice, dogs and pigs. Results from these studies show that the innate and adaptive immune systems of both the gut associated lymphoid tissue and the systemic immune system can be modified by fructooligosaccharides. However, there are few human studies so far which have investigated the effects of prebiotics on immune function, and these studies mostly rely on systemic markers of immunity. The results show little effect of fructooligosaccharides on innate immune function, but mixed results are reported regarding the adaptive immune system, suggesting that there may by improvement on this aspect of immunity with increased intake of fructooligosaccharides. The small number of published human studies led Watzl et al. (2005) to suggest that more human studies are needed to find out whether inulin and/or oligofructose have the potential to modulate systemic immunity in well-nourished individuals.

There are numerous methods available for assessing the human immune response. These have been evaluated by a panel of European experts (Albers et al. 2005). Based on its biological relevance, sensitivity and practical feasibility, response to vaccination was identified by this panel as the gold standard for measuring the functioning of the immune system in vivo (Albers et al. 2005). A small number of studies have studied the effect of fructooligosaccharides on the human immune response using vaccination response as the outcome, but only four of these examined fructooligosaccharides in the absence of other additional nutrients and of these two studies were in infants. Thus, the number of studies examining the immunologic impact of fructooligosaccharides in adult humans and using the gold standard outcome is very limited. From a public health perspective, it would be of importance, if fructooligosaccharides can improve immune function especially in older adults who are at risk of age-related immune decline. Thus, we propose to use a commercially available influenza vaccine (Imuvac®) to stimulate the immune response in healthy human adults, and to use this to assess the effect of a well defined prebiotic preparation commonly used in the food industry (Synergy1).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 45-65 years
  • Body mass index 20 to 32 kg/m2.
  • Not consuming probiotic supplements, yoghurts, drinks or other foods
  • Not consuming prebiotic supplemented drinks or foods
  • In general good health
  • No antibiotic use in the 2 months prior to entering the study or during the study
  • Not been vaccinated with the current season's influenza vaccine
  • Being able to provide written informed consent

Exclusion criteria

  • Aged < 45 or > 66 years
  • Body mass index < 20 or > 32 kg/m2.
  • Being diabetic (type 1 or type 2)
  • Displaying manifestations of allergy - asthma, hay-fever, dermatitis - or being treated for these
  • Being egg allergic
  • Use of any prescribed medicine (unless deemed to be acceptable by the PI)
  • Suffering from any infectious illness
  • Chronic gastrointestinal problems (e.g. IBD, IBS, cancer)
  • Recent blood donation
  • Participation in another clinical trial
  • Use of prebiotic or probiotic supplements, foods or drinks
  • Consuming vitamin, mineral or oil supplements
  • Previously vaccinated with the influenza vaccine being used.

Treatment and study plan

Prebiotic

Dietary Supplement

Inulin type fructooligosaccharides

Other names: Synergy1

Placebo

Dietary Supplement

Maltodextrin as placebo

Other names: Maltodextrin

Primary outcomes

  1. Serum anti-vaccine antibody concentrations

    Time frame: Weeks 2 and 4 post-vaccination

Secondary outcomes

  1. Serum total antibody (IgG, IgA, IgM) concentrations

    Time frame: Weeks -4, 0, 2 and 4 with respect to vaccination

  2. Innate immune responses - neutrophil and monocyte phagocytosis and respiratory burst

    Time frame: Weeks -4, 0, 2 and 4 with respect to vaccination

  3. Ex vivo T lymphocyte responses to mitogen (activation, proliferation and cytokine production)

    Time frame: Weeks -4, 0, 2 and 4 with respect to vaccination

  4. Ex vivo T lymphocyte responses to vaccine (activation, proliferation and cytokine production)

    Time frame: Weeks 0, 2 and 4 with respect to vaccination

  5. Ex vivo natural killer cell activity

    Time frame: Weeks -4, 0, 2 and 4 with respect to vaccination

  6. Faecal microflora

    Time frame: Weeks -4 and 0 with respect to vaccination

  7. Salivary IgA concentration

    Time frame: Weeks -4, 0, 2 and 4 with respect to vaccination

Sponsors and collaborators

Lead sponsor

University Hospital Southampton NHS Foundation Trust

Other

Collaborators

  • University of Southampton

Registry information

Official study title

Investigation of the Effects of a Prebiotic Supplement on Immune Function in Healthy Human Adults

Important dates

Study start
2009
Primary completion
2009
Study completion
2010
First posted
May 12, 2009
Registry last updated
Dec 2, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.